No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia

Acta Psychiatrica Scandinavica

Volumn 136, Issue 1, 2017, Pages 52-62

  Ishoy P L ^a,b   Fagerlund, B ^a,b   Broberg, B V ^a   Bak, N ^a   Knop, F K ^a,b   Glenthoj B Y ^a,b   Ebdrup, B H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

cognitive impairment; neurocognition; quality of life; randomized controlled trial; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROTHIXENE; CLOZAPINE; EXENDIN 4; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZUCLOPENTHIXOL; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; VENOM;

ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY ASSESSMENT; DOUBLE BLIND PROCEDURE; EXECUTIVE FUNCTION; FEMALE; GOOD CLINICAL PRACTICE; HUMAN; LEARNING; MALE; MENTAL PATIENT; MONOTHERAPY; MOTOR PERFORMANCE; OBESITY; OUTCOME ASSESSMENT; POLYPHARMACY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REY OSTERREITH COMPLEX FIGURE TEST; SCHIZOPHRENIA; SCHIZOPHRENIA ASSESSMENT; SCORING SYSTEM; SHORT FORM 36; SOCIAL PSYCHOLOGY; TREATMENT DURATION; VERBAL MEMORY; WORKING MEMORY; AGONISTS; COGNITIVE DEFECT; COMORBIDITY; COMPLICATION; DELAYED RELEASE FORMULATION; MIDDLE AGED; TREATMENT FAILURE; YOUNG ADULT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; COGNITIVE DYSFUNCTION; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; PEPTIDES; SCHIZOPHRENIA; TREATMENT FAILURE; VENOMS; YOUNG ADULT;

EID: 85014537141     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12711     Document Type: Article

References (54)

1. Kraepelin E. Psychiatrie: ein Lehrbuch für Studierende und Ärzte 1904;815–841.
2. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426–445.
3. Fett A-KJ, Viechtbauer W, Dominguez MDG, Penn DL, Van Os J, Krabbendam. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev 2011;35:573–588.
4. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull 2009;35:549–562.
5. De Hert M et al. The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics. CNS Drugs 2015;29:637–658.
6. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):3–8.
7. Higashi K et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 2013;3:200–218.
8. Dieset I, Andreassen OA, Haukvik UK. Somatic comorbidity in schizophrenia: some possible biological mechanisms across the life span. Schizophr Bull 2016;42:1316–1319.
9. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67–76.
10. Jagust W. What can imaging reveal about obesity and the brain? Curr Alzheimer Res 2007;4:135–139.
11. Messier C, Gagnon M. Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav Brain Res 1996;75:1–11.
12. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409–1439.
13. Madsbad S. A review of head-to-head comparisons of GLP-1 receptor agonists. Diabetes Obes Metab 2015;18:317–332.
14. Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131–2157.
15. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999;403:261–280.
16. Alvarez E et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 2005;92:798–806.
17. During MJ et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003;9:1173–1179.
18. Bertilsson G. et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson ‘s disease. J Neurosci Res 2008;338:326–338.
19. McClean PL, Gault VA, Harriott P, Hölscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010;630:158–162.
20. McClean PL, Parthsarathy V, Faivre E, Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011;31:6587–6594.
21. Ma T et al. Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. J Neurosci 2012;32:13701–13708.
22. Martin B et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of huntington ‘s disease. Diabetes 2009;58:318–328.
23. Bomba M et al. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis 2013;4:e612.
24. Gumuslu E et al. Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice. Fundam Clin Pharmacol 2016;30:376–384.
25. Siervo M et al. Intentional weight loss in overweight and obese individuals and cognitive function: a systematic review and meta-analysis. Obes Rev 2011;12:968–983.
26. McIntyre RS et al. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res 2013;237:164–171.
27. Ebdrup BH et al. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med 2012;10:92–99.
28. Ishøy PL, Knop FK, Vilsbøll T, Glenthøj BY, Ebdrup BH. Sustained weight loss after treatment with a glucagon-like Peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. Am J Psychiatry 2013;170:681–682.
29. Ishøy PL et al. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist — protocol for an investigator- initiated prospective, randomised, intervention study: the TAO study protocol. BMJ Open 2014;4:e004158.
30. Ishøy PL et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized. Placebo-controlled Trial Byline. Diabetes Obes Metab 2017;19:162–171.
31. Moher D et al. CONSORT 2010 Explanation and Elaboration : updated guidelines for reporting parallel group randomised trials. BMJ 2010;10:28–55.
32. Keefe RSE et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004;68:283–297.
33. Fastenau PS. Development and preliminary standardization of the ‘extended complex figure test’ (ECFT). J Clin Exp Neuropsychol 1996;18:63–76.
34. Hill SK et al. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. J Int Neuropsychol Soc 2008;14:209–221.
35. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009;23:315–336.
36. Irani F, Kalkstein S, Moberg EA, Moberg PJ. Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. Schizophr Bull 2011;37:1318–1326.
37. Keefe RSE. Brief Assessment of Cognition in Schizophrenia (BACS) Manual - A: Version 2.1. Durham: Duke University Medical Center, 1999.
38. Bjorner JB, Thunedborg K, Kristensen TS, Modvig J, Bech P. The Danish SF-36 Health Survey: translation and preliminary validity studies. J Clin Epidemiol 1998;51:991–999.
39. Aaronson NK et al. International quality of life assessment (IQOLA) project. Qual Life Res 1992;1:349–351.
40. Morosini P-L, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning. Acta Psychiatr Scand 2000;101:323–329.
41. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.
42. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med 2001;47:45–50.
43. Secher A et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014;124:4473–4488.
44. Heppner KM et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 2015;156:255–267.
45. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003;27:313–318.
46. Christensen M et al. Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. Int J Obes (Lond) 2015;39:1651–1654.
47. Gejl M et al. In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled. Double-blind clinical trial. Front Aging Neurosci 2016;8:108.
48. Mansur RB et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord 2016;207:114–120.
49. Fagerlund B, Mackeprang T, Gade A, Glenthøj BY. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr 2004;9:364–374.
50. Vella A, Jensen MD, Nair KS. Eulogy for the metabolic clinical investigator? Diabetes 2016;65:2821–2823.
51. Veronese N et al. Weight loss is associated with improvements in cognitive function among overweight and obese people: a systematic review and meta-analysis. Neurosci Biobehav Rev 2017;72:87–94.
52. Grant P, Lipscomb D, Quin J. Psychological and quality of life changes in patients using GLP-1 analogues. J Diabetes Complications 2011;25:244–246.
53. Fusar-Poli P et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 2015;41:892–899.
54. Keefe RSE et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull 2013;39:417–435.